Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Expert Opinion on Therapeutic Patents|November 22, 2011
Nicotinic acetylcholine receptor ligands, a patent review (2006-2011)Daniela Gündisch, Christoph EiblBioorganic & Medicinal Chemistry|May 22, 2012
Synthesis and evaluation of N(1)-alkylindole-3-ylalkylammonium compounds as nicotinic acetylcholine receptor ligandsEdwin G Pérez, Bruce K Cassels, Christoph Eibl, et al.Bioorganic & Medicinal Chemistry|October 23, 2013
The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor ligands. Part 2: carboxamide derivatives with different spacer motifsChristoph Eibl, Lenka Munoz, Isabelle Tomassoli, et al.Bioorganic & Medicinal Chemistry|October 26, 2013
The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor (nAChR) ligands. Part 1: the influence of different hydrogen bond acceptor systems on alkyl and (hetero)aryl substituentsChristoph Eibl, Isabelle Tomassoli, Lenka Munoz, et al.Pain Management|August 11, 2021
Tapentadol prolonged release in patients with chronic low back pain: real-world data from the German Pain eRegistryMichael A Überall, Christian Elling, Christoph Eibl, et al.The Journal of Pharmacology and Experimental Therapeutics|January 24, 2009
Cytisine-based nicotinic partial agonists as novel antidepressant compoundsYann S Mineur, Christoph Eibl, Grace Young, et al.The Journal of Pharmacology and Experimental Therapeutics|August 21, 2013
Differential modulation of brain nicotinic acetylcholine receptor function by cytisine, varenicline, and two novel bispidine compounds: emergent properties of a hybrid moleculeCan Peng, Clare Stokes, Yann S Mineur, et al.Journal of Pain Research|October 7, 2022
Multiple Dose Pharmacokinetics of Tapentadol Oral Solution for the Treatment of Moderate to Severe Acute Pain in Children Aged 2 to <7 YearsRenata Jończyk, Christoph Beuter, Beata Bulawa, et al.Pageof 1